ZURA - Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
As of May 15, 2026: spot at $4.67, ATM IV 114.4%, net GEX -$3.6K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $312.1M
- Beta
- 0.09
- 52-Week Range
- 0.98-7.44
- CEO
- Sandeep C. Kulkarni
- Employees
- 30
- IPO Date
- Mar 21, 2023
- Exchange
- NASDAQ
What ZURA Looks Like to Options Traders Today
IV rank of 24.8% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); negative net gamma exposure (-$3.6K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (-0.196) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The ZURA overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ZURA overview questions
- What is ZURA?
- ZURA is the ticker symbol for Zura Bio Limited, a listed security. Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. Listed on NASDAQ. ZURA is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ZURA options snapshot look like today?
- As of May 15, 2026, the ZURA options snapshot shows spot at $4.67, ATM IV 114.4%, IV rank 24.8%, net GEX -$3.6K, expected move 32.80%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ZURA's key statistics?
- Zura Bio Limited (ZURA) carries a market capitalization of $312.1M, beta of 0.09 relative to the broader market, 52-week range of 0.98-7.44. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ZURA belong to?
- Zura Bio Limited operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ZURA's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ZURA data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).